GSK drops lung injury drugs as respiratory clear-out continues

GSK drops lung injury drugs as respiratory clear-out continues

Source: 
Fierce Biotech
snippet: 

GlaxoSmithKline has terminated 11 projects over the past 12 months. The respiratory franchise bore the brunt of the cuts at a time when some GSK staff were questioning the wisdom of investing in the field.

Almost half of the terminations affect respiratory drugs that advanced as far as phase 2 studies before being deemed surplus to requirements.